Professor of Oncology, Professor of Urology, Johns Hopkins University School of Medicine
Oncology
Dr. Samuel R. Denmeade, MD
Samuel R. Denmeade is an expert in the field of Oncology. He went to Columbia University College of Physicians & Surgeons. Columbia University College of Physicians & Surgeons is one of the top medical schools in the US. Columbia University College of Physicians & Surgeons is ranked 8/52 in Research/PrimaryCare. He received awards:"CMS Meaningful Use Stage 1 Certification", "Top Doctors:Baltimore Area" and "Top Doctors:Washington-Baltimore". Samuel R. Denmeade is a published doctor and has 101 publications published. The lastest was: 'Suppression of the tumorigenicity of prostatic cancer cells by gene(s) located on human chromosome 19p13.1-13.2.' Doctor Samuel R. Denmeade, MD accepts all Medicare patients.
Publications
- The influence of prednisone on the efficacy of docetaxel in men with metastatic castration-resistant prostate Cancer.
- Iterative design of emetine-based prodrug targeting fibroblast activation protein (FAP) and dipeptidyl peptidase IV DPPIV using a tandem enzymatic activation strategy.
- CCAAT/Enhancer binding protein β controls androgen-deprivation-induced senescence in prostate Cancer cells.
- Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate Cancer: results from a pilot clinical study.
- Clinical activity of enzalutamide in Docetaxel-naïve and Docetaxel-pretreated patients with metastatic castration-resistant prostate Cancer.
- Pharmacokinetics and toxicology of a fibroblast activation protein (FAP)-activated prodrug in murine xenograft models of human Cancer.
- The effect of the frequency and duration of PSA measurement on PSA doubling time calculations in men with biochemically recurrent prostate Cancer.
- Proteolysis of Complement Factors iC3b and C5 by the Serine Protease Prostate-Specific Antigen in Prostatic Fluid and Seminal Plasma.
- Quantification of Mesenchymal Stem Cells (MSCs) at Sites of Human Prostate Cancer.
- A phase I/IIA study of AGS-PSCA for castration-resistant prostate Cancer.
- Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for Cancer therapy.
- Trypsin-like proteolytic contamination of commercially available psa purified from human seminal fluid.
- The unfolding treatment landscape for men with castration-resistant prostate Cancer.
- Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (Prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant Prostate ca...
- Enzymatically active prostate-specific antigen promotes growth of human prostate Cancers.
- Synthesis and cytotoxic activities of some 2-Arylnaphtho[2,3-d]oxazole-4,9-dione derivatives on androgen-dependent (LNCaP) and androgen-independent (PC3) human prostat...
- Bipolar androgen therapy: the rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate Cancer.
- Molecular processes leading to aberrant androgen receptor signaling and castration resistance in prostate Cancer.
- Prostate-specific antigen (PSA) is activated by KLK2 in prostate Cancer ex vivo models and in prostate-targeted PSA/KLK2 double transgenic mice.
- Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate Cancer.
- Molecular insights into substrate specificity of Prostate specific antigen through structural modeling.
- Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate Cancer.
- Amino acid containing thapsigargin analogues deplete androgen receptor protein via synthesis inhibition and induce the death of prostate Cancer cells.
- Targeting the Cancer stroma with a fibroblast activation protein-activated promelittin protoxin.
- Prostate-specific antigen is a "chymotrypsin-like" serine protease with unique P1 substrate specificity.
- Knockin of mutant PIK3CA activates multiple oncogenic pathways.
- Left posterior fascicular block due to high-dose interleukin-2.
- Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate Cancer.
- Characterization of a targeted nanoparticle functionalized with a urea-based inhibitor of Prostate-specific membrane antigen (PSMA).
- Mechanistic insights into the inhibition of Prostate specific antigen by beta-lactam class compounds.
- Fibroblast activation protein peptide substrates identified from human collagen I derived gelatin cleavage sites.
- A prostate-specific antigen activated N-(2-hydroxypropyl) methacrylamide copolymer prodrug as dual-targeted therapy for prostate Cancer.
- Preclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate Cancer demonstrate the inadequacy of PSA response as a primary endpo...
- A Prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease.
- Phase II study of imatinib mesylate in patients with prostate Cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiothe...
- Does PSA play a role as a promoting agent during the initiation and/or progression of prostate Cancer?
- The N-Myc down regulated Gene1 (NDRG1) Is a Rab4a effector involved in vesicular recycling of E-cadherin.
- Cytotoxic phenylpropanoids and an additional thapsigargin Analogue isolated from Thapsia garganica.
- A dimeric peptide that binds selectively to Prostate-specific membrane antigen and inhibits its enzymatic activity.
- Phase II evaluation of docetaxel plus exisulind in patients with androgen independent prostate Carcinoma.
- Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic Cancers.
- Comparative study of PSMA expression in the Prostate of mouse, dog, monkey, and human.
- Pharmacokinetics, biodistribution, and antitumor efficacy of a human Glandular kallikrein 2 (hK2)-activated thapsigargin prodrug.
- Synthesis and screening of a random dimeric peptide library using the one-bead-one-dimer combinatorial approach.
- Activity of irinotecan and the tyrosine kinase inhibitor CEP-751 in medullary thyroid Cancer.
- Applying linear interaction energy method for rational design of noncompetitive allosteric inhibitors of the sarco- and endoplasmic reticulum calcium-ATPase.
- The SERCA pump as a therapeutic target: making a "smart bomb" for prostate Cancer.
- Screening a combinatorial peptide library to develop a human Glandular kallikrein 2-activated prodrug as targeted therapy for prostate cancer.
- Use of methotrexate-based peptide substrates to characterize the substrate specificity of Prostate-specific membrane antigen (PSMA).
- Development of prostate Cancer treatment: the good news.
- Anti-tumor effect of combination therapy with intratumoral controlled-release paclitaxel (PACLIMER microspheres) and radiation.
- CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid Carcinoma cell growth.
- Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate Cancer.
- Prostate-specific antigen (PSA) protein does not affect growth of prostate Cancer cells in vitro or prostate Cancer xenografts in vivo.
- Dissociation between androgen responsiveness for Malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate canc...
- Trk receptor inhibition induces apoptosis of proliferating but not quiescent human osteoblasts.
- Thapsigargin analogues for targeting programmed death of androgen-independent prostate Cancer cells.
- HIF-1alpha and calcium signaling as targets for treatment of prostate Cancer by cardiac glycosides.
- Combinatorial androgen receptor targeted therapy for prostate Cancer.
- Deletion of p53 in human mammary epithelial cells causes chromosomal instability and altered therapeutic response.
- Design, synthesis, and pharmacological evaluation of thapsigargin analogues for targeting apoptosis to prostatic Cancer cells.
- Pan-trk inhibition decreases metastasis and enhances host survival in experimental models as a result of its selective induction of apoptosis of prostate Cancer cells.
- Activation of latent protease function of pro-hK2, but not pro-PSA, involves autoprocessing.
- Concentration of enzymatically active prostate-specific antigen (PSA) in the extracellular fluid of primary human prostate Cancers and human prostate Cancer xenograft ...
- Expression of prostate-specific membrane antigen in transitional cell carcinoma of the Bladder: prognostic value?
- In vivo activity of a PSA-activated doxorubicin prodrug against PSA-producing human prostate Cancer xenografts.
- Delayed micromolar elevation in intracellular calcium precedes induction of apoptosis in thapsigargin-treated breast Cancer cells.
- Thapsigargin induces a calmodulin/calcineurin-dependent apoptotic cascade responsible for the death of prostatic Cancer cells.
- Complete androgen blockade for prostate Cancer: what went wrong?
- Inhibition of caspase activity does not prevent the signaling phase of apoptosis in prostate Cancer cells.
- Assessment and validation of a microinjection method for kinetic Analysis of [Ca2+]i in individual cells undergoing apoptosis.
- Suppression of the tumorigenicity of prostatic Cancer cells by gene(s) located on human chromosome 19p13.1-13.2.
- Androgens regulate vascular endothelial growth factor content in normal and Malignant prostatic tissue.
- Enzymatic activation of a doxorubicin-peptide prodrug by Prostate-specific antigen.
- Enzymatic activation of prodrugs by prostate-specific antigen: targeted therapy for metastatic prostate Cancer.
- Mechanism and role of growth arrest in programmed (apoptotic) death of prostatic Cancer cells induced by thapsigargin.
- Specific and efficient peptide substrates for assaying the proteolytic activity of Prostate-specific antigen.
- Apoptosis in hormone-responsive Malignancies.
- Prostate Cancer: where are we and where are we going?
- Activation of programmed (apoptotic) cell death for the treatment of prostate Cancer.
- The genetics of programmed (apoptotic) cell death.
- Role of programmed (apoptotic) cell death during the progression and therapy for prostate Cancer.
- A supramicromolar elevation of intracellular free calcium ([Ca(2+)](i)) is consistently required to induce the execution phase of apoptosis.
- The role of Prostate-specific antigen in the clinical evaluation of prostatic disease.
- A phase II trial of temozolomide and IFN-alpha in patients with advanced renal cell Carcinoma.
- Phase I trial with a combination of docetaxel and ¹âµ³Sm-lexidronam in patients with castration-resistant metastatic prostate Cancer.
- Lenalidomide in nonmetastatic biochemically relapsed prostate Cancer: results of a phase I/II double-blinded, randomized study.
- Lack of an effect of high dose isoflavones in men with prostate Cancer undergoing androgen deprivation therapy.
- The change of PSA doubling time and its association with disease progression in patients with biochemically relapsed prostate Cancer treated with intermittent androgen...
- Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms Secondary to...
- Recombinant Prostate-specific antigen proaerolysin shows selective protease sensitivity and cell cytotoxicity.
- Modulating paclitaxel bioavailability for targeting prostate Cancer.
- Potent and selective peptidyl boronic acid inhibitors of the serine protease Prostate-specific antigen.
- Natural products as starting materials for development of second-generation SERCA inhibitors targeted towards prostate Cancer cells.
- Extended-release PEG-luciferin allows for long-term imaging of firefly luciferase activity in vivo.
- Optimization of peptide-based inhibitors of prostate-specific antigen (PSA) as targeted imaging agents for prostate Cancer.
- A Trojan horse in drug development: targeting of thapsigargins towards prostate Cancer cells.
- Prostate-specific antigen: an overlooked candidate for the targeted treatment and selective imaging of prostate Cancer.
- A combinatorial approach to the selective capture of circulating Malignant epithelial cells by peptide ligands.
- A history of prostate Cancer treatment.
Schools
Columbia University College of Physicians And Surgeons
University Of Chicago Hospitals and Health System
Johns Hopkins Hospital
Procedures Preformed
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Bladder Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
- Top Doctors:Baltimore Area
- Top Doctors:Washington-Baltimore
Education
-
Johns Hopkins University -
University of Chicago -
Columbia University College of Physicians & Surgeons
Hospital
-
Johns Hopkins Hospital -
Johns Hopkins Bayview Medical Center
Drug Facts
| NPI NUMBER | 1225073075 | |
| NPPES Provider LastName | DENMEADE | |
| NPPES Provider FirstName | SAMUEL | |
| NPPES Provider ZIPCode | 212870005 | |
| NPPES Provider State | MD | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 96.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 24.0 | |
| Percent Opioid Claims | 25.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1225073075 |
| Last Name Of The Provider | DENMEADE |
| First Name Of The Provider | SAMUEL |
| View All |
Similar Doctors
|
Dr. Matthew J. Frigault, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Enser W. Cole III, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Davis M. Hahn, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Timothy F. Burns, MD |
|
|
Dr. Trishna Goswami, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michele K. Evans, MD |
|
|
Ella Evon |